Literature DB >> 20232139

Identification of a new complex deleterious mutation in exon 18 of the BRCA2 gene in a hereditary male/female breast cancer family.

Orland Diez1, Sara Gutiérrez-Enríquez, Miriam Masas, Anna Tenés, Carme Yagüe, Angels Arcusa, Gemma Llort.   

Abstract

We report a novel complex mutation that consists of a deletion of 12 bp and an insertion of 2 bp (c.8402_8413del12ins2bp) in the exon 18 of the BRCA2 gene. This is a frameshift mutation that causes a disruption of the translational reading frame resulting in a stop codon downstream in the 2729 position of the BRCA2 protein. The mutation was present in a Spanish hereditary male/female breast cancer family.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20232139     DOI: 10.1007/s10549-010-0830-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  1 in total

1.  Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.

Authors:  L Moreno; C Linossi; I Esteban; N Gadea; E Carrasco; S Bonache; S Gutiérrez-Enríquez; C Cruz; O Díez; J Balmaña
Journal:  Clin Transl Oncol       Date:  2016-01-07       Impact factor: 3.405

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.